PI
NRIX icon

PEAK6 Investments’s Nurix Therapeutics NRIX Stock Holding History

PEAK6 Investments’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$225K Hold
10,000
– – ﹤0.01% 2728
2024
Q2 		$209K Buy
+10,000
New +$156K ﹤0.01% 2730

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

PEAK6 Investments's NRIX Position: Q3 2024 in Review

PEAK6 Investments held its Nurix Therapeutics (NRIX) position steady in Q3 2024 at 10,000 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #2728.

PEAK6 Investments first reported a position in NRIX in Q2 2024 and has held it in 2 quarters since. 172 funds tracked by Wall St. Rank hold NRIX as of Q3 2024.

  • PEAK6 Investments held 10,000 shares of Nurix Therapeutics worth $225K as of Q3 2024.
  • PEAK6 Investments left its Nurix Therapeutics share count unchanged in Q3 2024.
  • Nurix Therapeutics made up ﹤0.01% of PEAK6 Investments's portfolio in Q3 2024, its #2728 holding.
  • PEAK6 Investments first reported a position in Nurix Therapeutics in Q2 2024 and has held it in 2 quarters since.
  • 172 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2024.

Based on PEAK6 Investments's 13F filing for Q3 2024, filed 14 Nov 2024.